KR20030080296A - Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease - Google Patents

Abstract

PURPOSE: A composition containing a saponin fraction and a derivative thereof having an antiallergic effect separated from unprocessed Ginseng Radix or processed Ginseng Radix through chemical treatment and biological treatment is provided. Therefore, it has effective inhibitory activity on diseases associated with allergy and thus can be used as preventive and therapeutic agent against diseases associated with allergy. CONSTITUTION: The composition contains a saponin fraction separated from unprocessed Ginseng Radix or processed Ginseng Radix passed through chemical treatment such as acid treatment and biological treatment such as lactic acid culture and a derivative thereof separated therefrom. The saponin fraction is obtained by extracting dried Ginseng Radix in a mixed solvent for about 1 hr to 2 days at 20 to 100deg.C, suspending the extract in water and adding any one solvent of butanol, propanol or acetone to the suspension. The saponin derivative is selected from the group consisting of Rb1, Rb2, Re, Rg1, Rf, F1, Rh1, 20(S)-ginsenoside Rg3, 20(R)-ginsenoside Rg3, 20(S)-ginsenoside Rh2, 20(R)-ginsenoside Rh2 and a mixture thereof.

Description

COMPOSITION CONTAINING SAPONIN FRACTION AND DERIVATIVES ISOLATED FROM GINSENG RADIX FOR PREVENTING AND TREATING ALLERGY-MEDIATED DISEASE}

The present invention relates to a composition containing ginseng saponin derivative having excellent anti-allergic efficacy.

Due to the complexity of society and the development of industry and civilization, allergic diseases are increasing every year due to the increase of pollution in the natural environment, changes in diet and weight of stress. In 1980, less than 1% of allergic related patients, including atopic dermatitis, increased to more than 5% in the 2000s and more than 10% of potential patients. Allergy is a biochemical phenomenon that shows a specific and modified reaction to foreign substances (antigens, allergens), and when the released substances cause symptoms, allergens are called allergens. This is called. The cause of allergy is a pathological process of the living body that results from an antigenic antibody response, and is generally classified as type 1 to 4 according to the time required to cause the response and the type of complement-mediated. Immediate anaphylaxis, which causes bronchial asthma, allergic rhinitis, hay fever and atopic dermatitis, is a type 1 reaction. This immediate hypersensitivity and allergic reaction is due to various changes that occur in mast cells and the like. Mast cells are degranulation-induced activation of the antigen, binding of the antigen to the Fc receptor, anti-immunoglobulin E (anti-IgE), lectin (Lectin), stimulation of anaphylatoxin, calcium ionopo Caused by drugs such as synthetic cortical stimulating hormones such as Ionopore, compound K48 / 80, codeine, etc. (Tasaka et al., Ann.Allergy 56 , 464, 1986; Chand et al, Eur. J. Pharmacol., 96 , 227, 1983; Takei et al., J. Pharm. Sci., 84 , 223, 1995; Ohmori et al., Biol. Pharm. Bull., 18 , 683, 1995)

Recently, various studies have been conducted due to the increase of allergic diseases, and the development of radical immunology has made a lot of progress in the lifesaving and treatment of allergic diseases, but the development of drugs that can cure allergic diseases sufficiently. Existing allergic disease treatments include side effects such as dizziness, neurosensitivity, drowsiness and fatigue, so it is necessary to develop an allergic disease treatment agent that has excellent side effects while having fewer side effects.

Panax ginseng CAMeyer is a perennial root of perennial root, which belongs to the genus Ogapiaceae ginseng according to the taxonomy of plants. (1) Panax ginseng CAMeyer is a plant in the Far East of Asia (33-48 ° north: Korea, North Manchuria, It is native to parts of Russia and has very good efficacy. (2) American Ginseng ( Panax quinquefolium L.) grows and grows in the United States and Canada, and (3) Panax notoginseng FH Chen is located in the southwestern part of Guangxi province in southeastern Yunnan Province, China. Wild or cultivated in the region, and (4) Panax japonicus C.A.Meyer is known to be distributed in Japan, southwest China, and Nepal.

Ginseng is not only stored as a commodity in new agricultural plants, but has been used as a valuable medicine since ancient times. Many pharmacological experiments to date have revealed that ginseng strengthens the nonspecific resistance of the body to stress and has an acidic action. In addition, hypertension, insulin action enhancement, hypoglycemic effect in alloxan diabetic mice, liver RNA synthesis, protein synthesis, sugar and lipid metabolism promoting effect, and anticancer effect was found.

The ginseng has been used for various diseases such as psychiatric diseases, nervous system diseases and diabetes in the form of herbal medicine mainly in Asian countries such as Korea, China and Japan, and saponins, the main components of the ginseng, are tonic, gangjeong, soothing It is known to have effects on hematopoiesis and antihypertension. (和 漢 藥 百科 圖鑑, Vol. 1, pp. 1-8, Nambatsune-Hiki, Hoi-Kusa, 1980)

Ginseng is used in the form of red ginseng, which is produced by heat-treating white ginseng or ginseng dried at room temperature, or ginseng prepared by heating at 120 to 180 ° C.

The root of ginseng contains about 5.22% of ginseng saponin, which is a mixture of 13 or more types of saponins, among which the content of ginsenosides Rb1, Rc, and Rg1 is relatively high. Doha Hyangje Dictionary, Yeonglimsa, p439-443 1998)

There are about 300 kinds of enterobacteria of healthy people from the mouth to the rectum, and more than 98% of them are anaerobic bacteria, for example, Bacterioides, Eubacterium, Peptokocacea ( Peptococcaceae) and Bifidobacterium. These intestinal bacteria biologically convert the compounds contained in food or drugs, and the resulting transformants are often more physiologically active than the original compounds. One such example is saponins such as ginsenosides Rb1, Rb2, and Rc, which are main components in ginseng. Dual ginsenosides Rb1, Rb2 and Rc are metabolized mainly to compound K via ginsenoside Rd by the human intestinal flora. Known strains catalyzing this metabolic process are the Provotella oris and Fusobacterium K-60 strains. Meanwhile, when ginseng saponin is treated with a weak acid, it is converted to ginsenoside Rg3, and the compound is converted to ginsenoside Rh2 by intestinal bacteria such as Fusobacterium K-60 strain. Compound K and ginsenoside Rg3 produced in this case are known to inhibit cytotoxicity against cancer cells or cancer metastasis of cancer cells (Mochizuki, M. et al., Biol. Pharm. Bull ., 18, pp 1197- 1202, 1995; Wakabayashi, C., H. et al. , Oncol.Res . , 9, pp 411-417, 1998)

However, the prior art does not disclose any use of the composition containing the saponin derivative of the present invention as an agent for preventing and treating allergy-related diseases.

The present inventors have found that various kinds of saponin derivative compounds isolated from the ginseng saponin fraction produced by treating ginseng with lactic acid bacteria and enterobacteriaceae have an excellent therapeutic effect on allergic diseases and completed the present invention.

It is an object of the present invention to provide a composition containing ginseng saponin fractions and saponin derivatives effective for treating allergic related diseases.

In accordance with the above object, the present invention provides a composition for the prevention and treatment of allergic diseases containing saponin fractions isolated from ginseng extract and saponin derivatives isolated therefrom.

The composition for the prevention and treatment of allergic related diseases of the present invention comprises the ginseng fraction or derivative in an amount of 0.02 to 90% by weight based on the total weight of the composition.

The saponin fraction and saponin derivative of the present invention can be separated by performing a conventional method of separation in the art,

Looking specifically at the separation process,

(1) Acquisition process of saponin fraction

First, about 1 to 10 times, preferably about 5 to 8 times, water or lower alcohol or a mixture of about 1: 0.1 to 1:10, preferably 1: 1 to 1: 3 of the dried ginseng raw material. With a mixed solvent having an extraction process such as ultrasonic extraction, reflux extraction, cold soaking at about 20 to 100 ℃, preferably 70 to 80 ℃ extraction temperature at about 1 hour to 2 days, preferably about 2 hours to 1 day After performing this, it is suspended by dissolving it in water, and then adding about 1-5 times the volume of butanol, propanol, acetone solvent, preferably butanol solvent of the suspension to obtain a saponin fraction containing a large amount of saponin.

(2) Special Treatment Process of Saponin Fraction

0.01 to 50% of the weight / volume of the saponin fraction obtained in the above step, preferably 0.1 to 10% of the acid, preferably acetic acid, citric acid, lactic acid or acidic foods (e.g. Schisandra chinensis, etc.) are added to After culturing at an incubation temperature of 80 ° C., preferably 40 to 70 ° C. for 1 hour to 2 days, preferably 3 to 12 hours, the organic solvent is subsequently added to the culture to purify and separate the culture. Preferably, the solvent is extracted by adding an organic solvent selected from butanol, methanol, ether, and ethyl acetate. The extract is neutralized with a base to prepare a chemical acid-treated ginseng saponin fraction, followed by lactic acid bacteria or enteric bacteria. Added to the cultures for 12 hours to 4 days, preferably 24 hours to 3 days, at a culture temperature of 20 to 50 ° C., preferably 25 to 40 ° C. Main processing to obtain the saponin fractions.

Through this process, compounds ginsenoside-Rb1, ginsenoside-Rb2, and ginsenoside-Rc, which are contained in the raw materials, produce the first intermediate metabolite ginsenoside-Rg3 by lactic acid or enteric bacteria. It is bioconverted to convert the final metabolite, ginsenoside Rh2.

The ginseng raw materials include ginseng and processed ginseng products and by-products, and preferably include ginseng, red ginseng, white ginseng, rice ginseng, ginseng leaves, ginseng extract and powdered ginseng.

The lactic acid bacteria that can be used for the acid treatment of ginseng may be any one that can metabolize ginseng saponin to produce ginsenoside Rh2, preferably, Bifidobacterium lactic acid bacteria, more Preferably, Bifidobacterium K-103 (Professor Kim Dong-Hyun, Kyung Hee University, Arch. Pharm. Res. , 21 , pp54-61, 1988), Bifidobacterium K-506 (Professor Kim Dong-Hyun, Kyung Hee University, Arch. Pharm. Res. , 21 , pp54-61, 1988), Bifidobacterium K-513 (Refer to Professor Kim Dong-hyun, Kyung Hee University, Arch. Pharm.Res . , 21 , pp54-61, 1988), Bifidobacterium K-525 (See Professor Dong-Hyun Kim, Kyung Hee University, Arch. Pharm. Res. , 21 , pp54-61, 1988), Bifidobacterium KK-1 (Accession No .: KCCM 10364), Bifidoterium KK-2 (Accession No .: KCCM 10365) one or a mixed strain thereof selected from lactic acid bacteria can be used.

Intestinal bacteria that can be used in the culture can also be any one that can also metabolize ginseng saponin to produce ginsenoside Rh2, preferably Bacterioides genus, Fusobacterium Genus, Eubacterium genus enteric bacteria, more preferably bacterioides JY-6, bacterioides HJ-15 (Kim, Kyung Hee University College of Medicine, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000), Pusobacterium K-60 (Professor, Dong-Hyun Kim, Kyung Hee University, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000), Yoobacterium L-8 (Professor, Dong-Hyun Kim, Kyung Hee University, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000).

(3) Saponin derivative separation process

The saponin fraction obtained in step (1) or (2) is subjected to silica gel column chromatography to separate various kinds of saponin derivatives in separated form.

In another aspect, the present invention provides all related ginseng products that can be processed in the market containing the ginseng extract specially processed by the above-described manufacturing process.

Such processable related ginseng products include ginseng dry powder, extract, ampoule, tea, tablets and the like.

Raw or specially treated ginseng saponin fraction and ginseng saponin derivatives isolated therefrom are equivalent to or better than conventional antiallergic drugs in anti-allergic effect experiments in rat mast cells using RBL-2H3 cells. Excellent allergic inhibitory effect.

Accordingly, the present invention provides a pharmaceutical composition for the prevention and treatment of allergic diseases including saponin fraction and various kinds of saponin derivatives isolated therefrom.

Specifically, the allergy-related diseases include diseases such as rhinitis, dermatitis, asthma and autoimmune deficiency.

The composition comprising the ginseng saponin fraction of the present invention and saponin derivatives isolated therefrom may further comprise suitable carriers, excipients and diluents according to conventional methods.

As carriers, excipients and diluents that may be included in the composition comprising the ginseng saponin fraction of the present invention and saponin derivatives isolated therefrom, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch , Acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil Can be mentioned.

The composition comprising the ginseng saponin fraction and saponin derivatives isolated therefrom according to the present invention, powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. It can be formulated in the form of suppositories and sterile injectable solutions.

The ginseng saponin fraction of the present invention and the saponin derivatives isolated therefrom may vary depending on the age, sex, and weight of the patient, but the amount of 0.1 to 100 mg / kg may be administered once to several times daily. In addition, the dose of the ginseng saponin fraction and the saponin derivative separated therefrom may be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The composition comprising the ginseng saponin fraction of the present invention and the saponin derivative isolated therefrom can be used in various forms, such as drugs, foods and beverages for the prevention and treatment of allergic diseases. Examples of the food to which the present ginseng fraction and saponin derivative can be added include various foods, beverages, gums, teas, vitamin complexes, and health supplements.

Ginseng saponin fraction and saponin derivatives isolated from the ginseng of the present invention is a drug that can be used with confidence even for long-term use for the purpose of prevention because there is little toxicity and side effects.

The ginseng saponin fraction of the present invention and saponin derivatives isolated therefrom may be added to food or beverage for the purpose of preventing allergic related diseases. In this case, the amount of the ginseng saponin fraction and the saponin derivatives separated therefrom in the food or beverage may generally be added to 0.01-15% by weight of the total food weight, and the food health beverage composition may be 100 m1. Can be added at a ratio of 0.02 to 0.1 g, preferably 0.3 to 1 g.

The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the fractions or compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, like ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of said natural carbohydrate is generally about 1-20 g, preferably about 5-12 g per 100 m1 of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention is described in more detail based on the following examples, although the present invention is not limited thereto.

Example 1 Isolation of Ginseng Saponin Fraction and Saponin Derivatives

10 kg capacity of methanol was added to 1 kg of dried 6-year-old white ginseng purchased from Gyeongdong market, and cooled 5 times at room temperature, concentrated under reduced pressure to obtain 50 g of methanol extract (yield: 5%), and 300 ml of distilled water. After addition and suspension, 500 ml of butanol was added to the suspension, and the mixture was fractionated three times to obtain 15 g of saponin fraction, which was used as sample (1) .

1000 g of water containing 0.1% lactic acid was added to 15 g of this saponin fraction, and cultured at 60 ° C. for 5 hours to prepare acid-treated ginseng, neutralized by diluting with water, and diluted with lactic acid bacteria Bifidobacterium KK-1 (KCCM 10364). 15 g of Bifidobacterium KK-2 (KCCM 10365) strains (or Bacteroides HJ-15 strain and Bacteroides JY-6 strain, Kyung Hee University College of Medicine, Dong-Hyun Kim, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000) was added and incubated at 37 ° C. for 72 hours to extract this culture twice with 1000 ml of butanol, and concentrated under reduced pressure and dried to obtain 8.5 g of the processed saponin fraction powder, which was used as sample (2) . The obtained saponin fraction 8.5 was subjected to silica gel column chromatography (column size: 3.5 × 60 cm developing solvent: CHCl ₃ -MeOH = 10: 1) to give 200 mg of 20 (S) -ginsenoside Rg3, 20 (R) -ginseno Seed Rg3 80 mg, Δ ²⁰ -ginsenoside Rg3 60 mg, 20 (S) -ginsenoside Rh2 250 mg, 20 (R) - ginsenoside seed Rh2 8mg, Δ ²⁰ - ginsenoside seed Rh2 100mg, 20 (S) - Prototype wave incident diol 10mg, 20 (R) - Prototype wave incident diol 2mg, Δ ²⁰ - Prototype wave incident diol 5mg, Ginsenoside Rh1 100mg, Protopananaxatriol 12mg, Ginsenoside Rb1 40mg, Ginsenoside Rb2 30mg, Ginsenoside Re 20mg, Ginsenoside Rg1 120mg, Ginsenoside Rf 20mg, Ginsenoside Rf1 5mg These were used as a sample.

Example 2. Preparation of Ginseng Fermentation

To 1 kg of dried 6-year-old white ginseng purchased from Gyeongdong market, 50% water of 10 times was added, extracted three times at 50 ^o C, concentrated to obtain 70 g of extract (yield: 7%), and 300 ml of After distilled water was suspended, 500 g of Bifidobacterium KK-1 (KCCM 10364) and Bifidobacterium KK-2 (KCCM 10365) strains were added to 500 ml of this suspension at 37 ° C. Incubated for 72 hours, concentrated under reduced pressure and dried to obtain 120 g of a processed saponin fraction powder sample ( 3 ).

Experimental Example 1: Allergic inhibitory effect of saponin derivatives

(1) Experiment with RBL-2H3 cell line.

To compare the anti-allergic effect of the saponin fraction obtained in Example 1 of the present invention and the saponin derivatives isolated therefrom, Inagaki et al .; Int. Arch. Allergy Appl. Immunol., 87 , pp254-259, 1988) according to the anti-allergic test method described in the experiment was carried out as follows.

DBL (Dulbeccos' modified Eagle's medium, Sigma, 22256) containing 10% FBS (fetal bovine serum) and L-glutamine in rat mast cell line (RB-2H3 cell line, Cat Cell No. 22256) (Sigma D-5648) was incubated for 2 hours in a humidified 5% CO ₂ incubator at 37 ° C., and the adherent cells were suspended using trypsin-EDTA solution. It was used for this experiment.

The RBL-2H3 cells were aliquoted into ⁵ wells of ⁵ × 10 ⁵ cells / well, followed by sensitization by incubating for 12 hours with 0.5 μg / ml of mouse monoclonal IgE. The cells were washed with 0.5 ml of siraganian buffer (119 mM NaCl, 5 mM KCl, 0.4 mM MgCl ₂ , 25 mM PIPES, 40 mM NaOH, pH7.2) and then again 0.16 ml of siraguanian buffer (5.6 mM). Glucose, 1 mM CaCl ₂ , 0.1% BSA was added) and then incubated at 37 ° C. for 10 minutes. And the saponin fraction, the saponin derivatives and the control drug DSCG isolated in Example 1 each added 0.04 ml, and after 20 minutes with 0.02 ml of the antigen (DNP-BSA 1㎍ / ml) for 10 minutes at 37 ℃ Cells were activated and centrifuged at 2000 rpm for 10 minutes to transfer 0.025 ml of supernatant to 96 wells. To this was added 0.025 ml of substrate solution 1 mM p-NAG (a solution of p-nitrophenyl-N-acetyl-β-D-glucoamide) in 0.1M citrate buffer to pH 4.5, which was then heated at 37 ° C. After incubation for 10 minutes, 0.2 ml of 0.1 M Na ₂ CO ₃ / NaHCO ₃ was added to stop the reaction, and the respective absorbances were measured with an ELISA analyzer at 405 nm.

As shown in Table 1, the saponin fraction and the saponin derivatives isolated in Example 1 were equal to or superior to the allergic effect of RBL-2H3 cell line of DSCG (Disodium Cromoglycate, Sigma, C-0399) as a control drug. In addition to confirming, in particular, ginsenosides Rh1, Rh2 and F1 was also confirmed that the superior inhibitory effect than DSCG.

Antiallergic Effect in RBL Cells Treatment Sample IC ₅₀ (μg / ml) Saponin Fraction Samples (1) > 0.2 Saponin Fraction Samples (2) 0.1 Ginseng Fermentation 0.18 Ginseng Fermentation 0.15 Ginsenoside Rb1 > 0.2 Ginsenoside Rb2 > 0.2 Ginsenoside Re 0.06 Ginsenoside Rg1 0.08 Ginsenoside Rf 0.11 20 (S) -ginsenoside Rg 3 > 0.2 20 (R) -ginsenoside Rg 3 > 0.2 Δ ²⁰ -ginsenoside Rg3 0.09 Ginsenoside F1 0.13 20 (S) -ginsenoside Rh2 0.03 20 (R) -ginsenoside Rh2 > 0.2 Ginsenoside Rh1 0.02 20 (R) -protopanaxadiol > 0.2 20 (S) -protopanaxadiol > 0.2 DSCG (positive control) 0.498

(2) Passive Percutaneous Anaphylaxis Experiment Using Animal Model

In addition, the saponin fraction, the saponin derivative and the positive control group DSCG (Disodium Cromoglycate, Sigma, C-0399) of Example 1 on allergy using a passive cutaneous anaphylaxis experimental animal model were as follows. The same experiment was performed.

First, the back of the mouse (ICR-based Korean animal) in which 10 g of a solution of IgE serum of DNP-HSA (Dinitrophenol-human serum albumin (Sigma, A-6661) diluted with physiological saline was anesthetized with ether. (50 µl) and manually sensitized, and after 48 hours, 0.2 ml of saline solution containing 0.2 mg of DNP-HSA and 1.6 mg of evans blue was injected into the tail vein and killed by cervical dislocation 30 minutes later. The amount of Evans blue pigment leaked by the back and the like was measured. A portion of the back of the mouse (1cm ² of the site where IgE was injected) was cut out into a test tube, and 0.7 ml of 1N-KOH was added thereto and incubated overnight at 37 ° C. 4 ml of 0.6N phosphate-acetone mixed solution (5:13) was added to the test tube, followed by shaking with Vortex and filtration to give colorimetric determination at 620 nm.

Samples were dissolved or suspended in physiological saline and administered orally one hour before administration of antigen (DNP-BSA).

As shown in Table 2 below, the saponin fraction and the saponin derivatives isolated in Example 1 showed the same or more inhibitory effect on the allergy using the RBL-2H3 cell line of DSCG (Disodium Cromoglycate, Sigma, C-0399) Not only can it be confirmed that it is excellent, but also ginsenosides Rh1, Rh2 and F1 was also confirmed that the superior inhibitory effect than DSCG ((-) not shown)

Results of Passive Transdermal Anaphylaxis Effect Treatment Sample Capacity (mg / kg) % Inhibition Oral administration Intraperitoneal administration Saponin Fraction (Sample 1) 50 34 - Saponin Fraction (Sample 2) 50 47 - Ginsenoside Rb1 50 - 17 Ginsenoside Rb2 25 - 12 Ginsenoside Re 25 - 15 Ginsenoside Rg1 25 - 37 Ginsenoside Rf 25 - 40 20 (S) -ginsenoside Rg 3 25 38 47 Δ ²⁰ -ginsenoside Rg3 25 - 45 Ginsenoside F1 25 - 69 20 (S) -ginsenoside Rh2 25 36 88 Δ ²⁰ -ginsenoside Rg2 25 - 63 Ginsenoside Rh1 25 79 87 20 (S) -protopanaxadiol 25 - 25 DSCG (positive control) 100 37

In conclusion, the chemical treatment and biological treatment of ginseng produced a large amount of saponin derivatives effective for the prevention and treatment of allergic diseases. It has been found that it can be effective in the prevention and treatment of diseases.

Hereinafter, an example of the preparation of the pharmaceutical composition will be described, but it is not intended to limit the present invention but merely to explain in detail.

Formulation Example 1 Preparation of Powder

According to the preparation method of powder in the pharmacopeia formulation, it is prepared in the following component content per packet.

Ginsenoside Rh1 50 mg

Lactose · ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Talc 10 mg

Formulation Example 2 Preparation of Tablet

According to the preparation method of tablets in the pharmacopeia formulation, it is prepared in the following component content per tablet.

Ginsenosides Rh1 50 mg

Corn starch ㆍ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Lactose · ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Magnesium Stearate 2 mg

Formulation Example 3 Preparation of Capsule

According to the preparation method of the capsule in the general formulation of the pharmacopeia, it is prepared in the following component content per capsule.

Ginsenoside Rh1 ... 50 mg

Corn starch ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Lactose ····················· 100 mg

Magnesium stearate 2 mg

Formulation Example 4 Preparation of Injection

According to the preparation method of injection in the pharmacopeia formulation, it is prepared in the following component content per ampoules (2 ml).

Ginsenoside Rh1 ... 50 mg

Sterile distilled water for injection ㆍ ·············

pH regulator ㆍ ··················

Formulation Example 5 Preparation of Liquid

According to the preparation method of the liquid formulation in the Pharmacopoeia General Formulation, it is prepared in the following component content per 100 ml of the liquid formulation.

Ginsenoside Rh1 ... 50 mg

Heterosaccharides ················· 10 g

Mannitol ···················· 5 g

Purified water ㆍ ···················

In addition, the health beverage is prepared as follows.

Ginsenoside Rh1 0.1 ~ 80%, Sugar 5 ~ 10%, Citric acid 0.05 ~ 0.3%, Caramel 0.005 ~ 0.02%, Vitamin C 0.1 ~ 1% Additives and 79 ~ 94% purified water are mixed to make syrup To prepare a carbonated beverage containing ginseng saponin was made by sterilizing the syrup at 85 ~ 98 ℃ for 20 ~ 180 seconds, mixed with cooling water at a ratio of 1: 4 and then injected 0.5 ~ 0.82% of carbon dioxide gas.

Instant sterilization by homogeneously combining ginsenoside Rh1 with subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). Healthy drinks were prepared by packing them in small packaging containers such as bottles and plastic bottles.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and use purpose.

Compositions comprising saponin fractions and saponin derivatives isolated from processed ginseng, which have undergone chemical treatments such as raw ginseng or acid treatment and biological treatments such as lactic acid bacteria culture, have an activity that effectively inhibits allergic diseases. Since it shows a prophylactic and therapeutic effect of a disease, it can be usefully used as a prophylactic and therapeutic agent for allergic diseases.

Claims (11)

A pharmaceutical composition for preventing and treating allergic diseases comprising a saponin fraction separated from ginseng raw material or a saponin derivative separated therefrom as an active ingredient and a pharmaceutically acceptable carrier. The method of claim 1, The ginseng raw material is raw or processed through chemical treatment such as acid treatment and biological treatment such as lactic acid bacteria culture. The method of claim 1, The saponin fraction is a mixed solvent having a mixing ratio of about 1 to 10 times 15 times water, lower alcohol or about 1: 0.1 to 1:10 of the dried ginseng raw material at about 1 hour at 20 to 100 ° C extraction temperature. After performing extraction processes such as ultrasonic extraction, reflux extraction, and cold soaking in about 2 days, and then suspending it in water, the solvent of any one of about 1 to 5 times the volume of butanol, propanol or acetone solvent of the suspension is dissolved. The composition obtained by addition. The method of claim 1, Saponin derivatives include ginsenosides Rb1, Rb2, Re, Rg1, Rf, F1, Rh1, 20 (S) -ginsenosides Rg3, 20 (R) -ginsenosides Rg3, 20 (S) -ginsenosides Rh2, 20 (R) -ginsenoside Rh2 and a mixture thereof. The method of claim 4, wherein Wherein the saponin derivative is ginsenoside Rh1, Rh2 or F1. The method according to any one of claims 1 to 4, A pharmaceutical form used in the form of a pharmaceutical composition is any one selected from powders, granules, tablets, capsules, solutions, injections. A dietary supplement comprising a saponin derivative alone or a mixture thereof separated from ginseng raw materials and a food acceptable additive. The method of claim 7, wherein The ginseng raw material is unprocessed or health supplements through chemical treatment such as acid treatment and biological treatment such as lactic acid bacteria culture. The method of claim 7, wherein Saponin derivatives include ginsenosides Rb1, Rb2, Re, Rg1, Rf, F1, Rh1, 20 (S) -ginsenosides Rg3, 20 (R) -ginsenosides Rg3, 20 (S) -ginsenosides Rh2, A dietary supplement selected from the group consisting of 20 (R) -ginsenoside Rh2 and mixtures thereof. The method of claim 7, wherein A dietary supplement wherein the saponin derivative is ginsenosides Rh1, Rh2, F1. The method of claim 7, wherein Health supplements in the form of healthy drinks.